IDEAYA Biosciences (IDYA) Cash & Equivalents (2018 - 2026)

IDEAYA Biosciences (IDYA) has 9 years of Cash & Equivalents data on file, last reported at $157.5 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents rose 59.86% year-over-year to $157.5 million; the trailing twelve-month figure through Mar 2026 stood at $157.5 million (up 59.86% YoY), and the FY2025 full-year result was $112.8 million, up 33.71% from the prior year.
• Cash & Equivalents grew to $157.5 million in Q1 2026, from $112.8 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $400.3 million in Q3 2024 to a low of $49.1 million in Q2 2022.
• A 5-year average of $136.0 million and a median of $108.3 million in 2024 frame the typical range for Cash & Equivalents.
• Across the five-year window, Cash & Equivalents tumbled 59.57% in 2022 and surged 163.6% in 2024, its largest moves.
• Tracing IDYA's Cash & Equivalents over 5 years: stood at $68.6 million in 2022, then soared by 128.78% to $157.0 million in 2023, then slumped by 46.26% to $84.4 million in 2024, then surged by 33.71% to $112.8 million in 2025, then jumped by 39.62% to $157.5 million in 2026.
• Business Quant data shows IDYA's Cash & Equivalents at $157.5 million in Q1 2026, $112.8 million in Q4 2025, and $298.9 million in Q3 2025.